HIV-suppressing Protein Discovered In Infected Blood
A major breakthrough in finding the elusive HIV cure has been achieved by researchers based in Washington. They discovered a protein in HIV-infected people capable of suppressing the virus. Canadian pharmacies believe researchers working at the Laboratory of Immunoregulation located at the National Institute of Allergy and Infectious Diseases (NIAID) have succeeded in isolating a protein known as CXCL4 or PF4 in the laboratory capable of binding itself to the HIV virus and preventing it from affecting normal cells.
Research conducted in the mid-1990s revealed chemokines through laboratory tests producing similar results. The chemokines were capable of inhibiting the HIV virus in laboratory experiments. However, experiments did not provide the complete answer even though immune cell regulation in the body could be successfully conducted.
Findings from the present research holds great importance, as researchers believe a combination of CXCL4 and chemokines may actually help in stemming growth of HIV virus thereby dictating the pace at which it spreads through the human body. Researchers at the NIAID Vaccine Research Center are focusing on identifying the crystalline structure of the binding site at the atomic level. They believe a cure can be found in the form of a HIV vaccine. At present, patients buy Atripla from Canadian pharmacies for effective HIV treatment.
The CXCL4 protein is an addition to four other chemokines discovered earlier. It binds itself to the outer coating of the HIV virus, and the area appears different under the microscope when compared to other infected sites treated with other HIV-blocking prescription drugs and antibodies. The difference made researchers study differences between CXCL4 and other chemokines.
Earlier research established infection caused by HIV virus could be inhibited when the chemokine bound itself to either CXCR4 or CCR5, two cell receptors identified during earlier studies. It regulated the HIV virus by manipulating the receptors. However, CXCL4 directly attached itself to the outer surface of HIV virus cells. Scientists believe this is a major finding that will help prevent HIV virus from spreading. Also, the CXCL4 protein was found to offer protection against any HIV virus stream, whereas earlier chemokines were effective in blocking only HIV virus using either CXCR4 or CCR5 receptors.
According to the International Symposium on HIV and Emerging Infectious Diseases (ISHEID), the first HIV-infected patient from Berlin has already been cured of HIV/AIDS. Discussions were held in Marseilles, France about the extent of research activity aimed at finding a permanent cure for HIV/AIDS. Clinical data accumulated thus far has been able to identify the route to be taken. The present research is one of several attempts made by institutions across the world trying to find a fast HIV solution.
Laboratory tests also found a major difference in the way CXCL4 affects the HIV virus. Chemokines were made of immune cells and fought viral attacks by producing antibodies. CXCL4, on the other hand, is derived from blood cells preventing clotting, namely platelets. These findings are now to be tested out of a laboratory setting. People infected with the HIV virus must respond positively in the same manner.
At present, Canadian drugs are very effective in treating HIV-infected patients and works by stopping the production of the virus. Canadian pharmacies are convinced scientists are in the right direction and hopes a permanent cure for HIV/AIDS will be found in the near future.